Ablynx [Euronext Brussels: ABLX], today announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth
GHENT, BELGIUM | September 30, 2009 | Ablynx [Euronext Brussels: ABLX], today announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $4 million has been triggered by the initiation by Wyeth of a first Phase II multiple dose study in patients with rheumatoid arthritis (RA) for a Nanobody targeting tumour necrosis factor alpha (TNF-alpha).
Wyeth entered into a Phase I study in healthy volunteers in December 2008 in the USA and Japan. Based on a successful conclusion of that study, where the Nanobody was safe and well tolerated, Wyeth has today initiated a multiple dose Phase II study in RA patients. Ablynx entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals in November 2006, a deal potentially worth $212.5 million for the successful development and commercialisation of multiple products. In addition, Ablynx is eligible to receive royalties on product sales. Wyeth has exclusive rights to develop and commercialise anti-TNF-alpha Nanobodies developed under the collaboration. TNF-alpha is a key drug target in combating inflammation related disorders such as rheumatoid arthritis, Crohn’s disease, psoriatic arthritis and ankylosing spondylitis.
Dr Edwin Moses, CEO and Chairman of Ablynx commented: "After a successful Phase I study in healthy volunteers in the USA and Japan, we are delighted that Wyeth has progressed the TNF-alpha programme into a Phase II study in patients with RA. Therapeutics targeting TNF-alpha generated $16.8 billion in sales in 2008, and Wyeth Pharmaceuticals is well positioned with its Enbrel franchise to progress this Nanobody programme towards the market and create another great success."
SOURCE: Ablynx
Post Views: 60
Ablynx [Euronext Brussels: ABLX], today announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth
GHENT, BELGIUM | September 30, 2009 | Ablynx [Euronext Brussels: ABLX], today announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $4 million has been triggered by the initiation by Wyeth of a first Phase II multiple dose study in patients with rheumatoid arthritis (RA) for a Nanobody targeting tumour necrosis factor alpha (TNF-alpha).
Wyeth entered into a Phase I study in healthy volunteers in December 2008 in the USA and Japan. Based on a successful conclusion of that study, where the Nanobody was safe and well tolerated, Wyeth has today initiated a multiple dose Phase II study in RA patients. Ablynx entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals in November 2006, a deal potentially worth $212.5 million for the successful development and commercialisation of multiple products. In addition, Ablynx is eligible to receive royalties on product sales. Wyeth has exclusive rights to develop and commercialise anti-TNF-alpha Nanobodies developed under the collaboration. TNF-alpha is a key drug target in combating inflammation related disorders such as rheumatoid arthritis, Crohn’s disease, psoriatic arthritis and ankylosing spondylitis.
Dr Edwin Moses, CEO and Chairman of Ablynx commented: "After a successful Phase I study in healthy volunteers in the USA and Japan, we are delighted that Wyeth has progressed the TNF-alpha programme into a Phase II study in patients with RA. Therapeutics targeting TNF-alpha generated $16.8 billion in sales in 2008, and Wyeth Pharmaceuticals is well positioned with its Enbrel franchise to progress this Nanobody programme towards the market and create another great success."
SOURCE: Ablynx
Post Views: 60
